Proton Therapy Market in Switzerland - Reimbursement Policy, Patients Treated at Proton Facility & Forecast - Research and Markets
South Korea Proton Therapy Market - Expected to Almost Triple by 2021 from its Current Market Size in 2016 - Research and Markets
Energy Based Ablation Devices - Global Strategic Business Report 2017 - Research and Markets
Varian Medical's VAR third-quarter fiscal 2006 results fall right in line with the seasonal patterns we expected from our current near-term modeling assumptions. The oncology group notched 14% growth, and customer demand continues to reflect a shift toward Varian's next-generation IGRT technology, ...
Varian Medical Systems' VAR third-quarter results were in line with our expectations, and we are leaving our fair value estimate unchanged. Overall, revenue increased 7%, and net orders rose 13%, bringing the company's backlog at quarter-end to $1.6 billion. Revenue for the oncology system segment ...
Despite the sector looking slightly overvalued, we still see stocks with attractive valuations across the different industries.
Despite the sector looking slightly overvalued overall, we still see stocks that offer attractive valuations across the different industries.
The combination makes plenty of sense and should better position the firm for the future.
While the sector looks slightly overvalued overall, we still see several stocks that offer attractive valuations across the different industries.